Akebia Therapeutics, INC 8-K filings

Akebia Therapeutics and U.S. Renal Care announce the VOICE trial met its primary composite endpoint, demonstrating non-inferiority and superiority of Vafseo versus standard-of-care ESA.

Akebia Therapeutics reported Q1 2026 financial results, showing Vafseo net product revenues of $15.8 million and a 60% increase in treated patients, alongside progress in its kidney disease pipeline.

Akebia Therapeutics strengthens its Board of Directors with the appointment of biopharmaceutical leader Philip Vickers, Ph.D., following the retirement of Steven C. Gilman, Ph.D.

Akebia Therapeutics announced robust financial results for Q4 and full-year 2025, driven by significant Vafseo revenue growth and pipeline advancements.

Akebia Therapeutics has signed a new lease for its corporate headquarters and laboratory space in Waltham, Massachusetts, and updated severance agreements for its CEO and CFO.

Akebia Therapeutics announced key corporate updates for its Vafseo commercial business and provided an outlook on upcoming milestones for its mid-stage rare kidney disease pipeline, including expected Q4 2025 Vafseo net product revenue.

Akebia Therapeutics establishes a rare kidney disease pipeline by acquiring AKB-097 from Q32 Bio and initiating a Phase 2 trial for praliciguat.

Akebia Therapeutics and Medice amend their Vafseo license agreement, with Akebia now supplying drug substance and Medice gaining manufacturing rights.

Akebia Therapeutics reported strong third-quarter 2025 financial results, achieving net income and significant growth in Vafseo and Auryxia product revenues.

Akebia Therapeutics will not pursue a broad label for Vafseo in non-dialysis dependent chronic kidney disease patients after failing to align with the FDA on a clinical trial design.

Akebia Therapeutics announced a return to net income in Q2 2025, driven by significant growth in Vafseo sales and strategic partnerships.

Akebia Therapeutics, Inc. announced that its stockholders approved an amendment to its 2023 Stock Incentive Plan, increasing available shares by 18.9 million, alongside the re-election of two Class II directors and other key proposals at its Annual Meeting.

Akebia Therapeutics announces positive Q1 2025 results driven by a strong Vafseo launch, with net product revenues reaching $12.0 million.

Akebia Therapeutics has priced its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share, expecting gross proceeds of $50 million.

Akebia Therapeutics announces strong initial results from the Vafseo U.S. launch and anticipates Q1 2025 net product revenues of $10-$11 million.

Akebia Therapeutics amends its loan agreement with Kreos Capital, extending and drawing down a $10 million tranche while issuing warrants for common stock.

Akebia Therapeutics has commenced the U.S. commercial launch of Vafseo for anemia in dialysis patients and is planning a Phase 3 trial for non-dialysis patients, while also advancing its pipeline.

Akebia Therapeutics announced its third quarter 2024 financial results, highlighting progress in the commercial launch of Vafseo and ongoing efforts to expand its market presence.

Akebia Therapeutics has signed a multi-year commercial supply agreement with a leading dialysis organization to expand access to Vafseo (vadadustat) for patients on dialysis.

Akebia Therapeutics has extended its supply agreement with STA Pharmaceutical for vadadustat drug product until January 1, 2032, and amended the pricing structure.

Akebia Therapeutics announced its second quarter 2024 financial results, highlighted by progress in the commercial launch of Vafseo and Auryxia revenue updates.

Akebia Therapeutics has terminated its license agreement with CSL Vifor for Vafseo and amended its loan agreement with Kreos Capital, effective July 10, 2024.

Akebia Therapeutics has appointed Erik Ostrowski as its new Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer, and principal financial officer, effective June 24, 2024.

Akebia Therapeutics held its annual meeting on June 6, 2024, where three directors were elected, executive compensation was approved, and the selection of Ernst & Young as auditor was ratified, but a proposal to increase the number of shares available under the stock incentive plan was not approved.

Akebia Therapeutics reported its first quarter 2024 financial results, highlighted by the FDA approval of Vafseo and ongoing launch preparations.

Akebia Therapeutics has drawn down $7.5 million from its loan facility with Kreos Capital, adding to the initial $37 million received earlier this year.

Akebia Therapeutics has extended its supply agreement with STA Pharmaceutical for the manufacturing of vadadustat drug substance by five years, now expiring in 2029, and has also amended the pricing structure.

Akebia Therapeutics has secured FDA approval for Vafseo (vadadustat) tablets, a new oral treatment for anemia in adult patients on dialysis due to chronic kidney disease.

Akebia Therapeutics' Chief Financial Officer, Ellen Snow, will transition out of her role on March 22, 2024, with CEO John Butler stepping in as interim CFO.

Akebia Therapeutics announced its fourth quarter and full year 2023 financial results, highlighted by Auryxia revenue within guidance and preparations for a potential vadadustat launch, pending FDA approval.